Effect of Chemotherapy and Predictive Factors for Nausea or Vomiting in Patients with Cancer Receiving Opioid Analgesics for the First Time

2020 ◽  
Vol 15 (3) ◽  
pp. 213-220
Author(s):  
Masami Yamada ◽  
Chikako Matsumura ◽  
Yumi Jimaru ◽  
Rie Ueno ◽  
Sari Torii ◽  
...  
Critical Care ◽  
2014 ◽  
Vol 18 (Suppl 1) ◽  
pp. P58
Author(s):  
L Hajjar ◽  
M Franca ◽  
J Almeida ◽  
J Fukushima ◽  
F Bergamin ◽  
...  

2019 ◽  
Vol 24 (7) ◽  
Author(s):  
Kosuke Takahashi ◽  
Masashi Kondo ◽  
Masahiko Ando ◽  
Akira Shiraki ◽  
Harunori Nakashima ◽  
...  

2017 ◽  
Vol 354 (2) ◽  
pp. 125-130 ◽  
Author(s):  
Jaehee Lee ◽  
Yong Dae Lee ◽  
Jae Kwang Lim ◽  
Deok Heon Lee ◽  
Seung Soo Yoo ◽  
...  

Cancers ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 49
Author(s):  
Maria D’Souza ◽  
Mette Bagger ◽  
Mark Alberti ◽  
Morten Malmborg ◽  
Morten Schou ◽  
...  

Purpose: To estimate the frequency of first-time ocular events in patients treated with immune checkpoint inhibitors (ICI). Methods: Patients with cancer in 2011–2018 in Denmark were included and followed. The outcomes were first-time ophthalmologist consultation and ocular inflammation. One-year absolute risks of outcomes and hazard ratios were estimated. Results: 112,289 patients with cancer were included, and 2195 were treated with ICI. One year after the first ICI treatment, 6% of the patients with cancer, 5% and 8% of the lung cancer (LC) and malignant cutaneous melanoma (MM) patients, respectively, had a first-time ophthalmologist consultation. The risk of ocular inflammation was 1% (95% confidence interval (CI) 0.4–1.2). Among patients with MM, ICI was associated with ocular inflammation in women (HR 12.6 (95% CI 5.83–27.31) and men (4.87 (95% CI 1.79–13.29)). Comparing patients with and without ICI treatment, the risk of first-time ophthalmologist consultation was increased in patients with LC (HR 1.74 (95% CI 1.29–2.34) and MM (HR 3.21 (95% CI 2.31–4.44). Conclusions: The one-year risks of first-time ophthalmologist consultation and ocular inflammation were 6% and 1%, respectively, in patients treated with ICI. In patients with LC and MM, the risk was increased in patients with ICI compared with patients without ICI.


2007 ◽  
Vol 3 (4) ◽  
pp. 207 ◽  
Author(s):  
Ramune Jacobsen, MS, MPH ◽  
Per Sjøgren, MD, DMS ◽  
Claus Møldrup, PhD ◽  
Lona Christrup, PhD

Objective: The purpose of this review is to summarize the results of studies on physician-related barriers to cancer pain management with opioid analgesics.Methods: A literature search was conducted in PUBMED, using a combined text word and MeSH heading search strategy. Those articles whose full texts were not available in PUBMED were retrieved from the electronic databases of specific journals.Results: Sixty-five relevant articles, published in the period from 1986 to 2006, were identified. Physicians’ barriers to cancer pain management were studied in questionnaire surveys and in the reviews of drug prescribing documents. The results of the articles found were analyzed with respect to (a) knowledge, beliefs, concerns, problems endorsed or acknowledged by physicians treating cancer pain, (b) physicians’ skills in pain assessment, and (c) adequacy of opioid prescription.Conclusions: This review revealed mostly general and common physician-related barriers to cancer pain management: concerns about side effects to opioids, prescription of not efficient doses of opioids, and very poor prescription for the treatment of side effects from opioids. In the future, the evaluation of the influence of cultural-social-economical background, as well as the differences between the various specialists involved in the care of patients with cancer, should be explored to better understand physicians’ barriers and more effectively address them in interventional and educational programs.


Sign in / Sign up

Export Citation Format

Share Document